Target Name: DCSTAMP
NCBI ID: G81501
Review Report on DCSTAMP Target / Biomarker Content of Review Report on DCSTAMP Target / Biomarker
DCSTAMP
Other Name(s): Dendrocyte-expressed seven transmembrane protein | MGC138225 | IL-four-induced protein | hDC-STAMP | OTTHUMP00000227835 | IL-4-induced protein | Dendrocyte expressed seven transmembrane protein, transcript variant 2 | Dendrocyte expressed seven transmembrane protein, transcript variant 1 | DCSTP_HUMAN | Transmembrane 7 superfamily member 4 (TM7SF4) | DCSTAMP variant 2 | Dendritic cell-specific transmembrane protein (isoform 2) | Dendritic cells (DC)-specific transmembrane protein | Transmembrane 7 superfamily member 4 | IL-Four (IL-4) induced | FIND | DC-STAMP | DCSTAMP variant 1 | TM7SF4 | DC-specific transmembrane protein | Dendritic cell-specific transmembrane protein (isoform 1) | Dendritic cell-specific transmembrane protein | transmembrane 7 superfamily member 4 | MGC138223 | IL-Four INDuced | dendrocyte expressed seven transmembrane protein

DCSTAMP: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant disability and reduced quality of life. The underlying mechanisms of chronic pain are complex, and scientists are still trying to understand the exact mechanisms that drive it. However, one of the known causes of chronic pain is the over-expression of certain genes, including those involved in pain signaling. One such gene is DCSTAMP (Dendrocyte-expressed seven transmembrane protein), which has been identified as a potential drug target and biomarker for chronic pain.

In this article, we will discuss the biology of DCSTAMP, its expression in chronic pain models, and its potential as a drug target. We will also explore the research being done to develop DCSTAMP-based therapies for the treatment of chronic pain.

DCSTAMP: A Potential Drug Target

DCSTAMP is a seven-transmembrane protein that is expressed in dendrocytes, which are the brain cells responsible for transmitting pain signals. The protein is expressed in high levels in individuals with chronic pain, and its expression has been linked to the development of pain-related behaviors.

Studies have shown that DCSTAMP is involved in pain signaling by modulating the activity of pain-related GABA receptors. GABA is a neurotransmitter that has been shown to play a crucial role in pain modulation. The activity of GABA receptors is increased in individuals with chronic pain , and this increase in activity is thought to contribute to the persistent nature of pain.

DCSTAMP has also been shown to interact with other proteins involved in pain signaling, including the transduction molecule TRPV1 and calcium ions Ca2+. These interactions may play a role in the regulation of pain signaling.

DCSTAMP as a Biomarker

DCSTAMP has also been shown to be a potential biomarker for chronic pain. The expression of DCSTAMP has been shown to be associated with the development of pain-related behaviors in animal models of chronic pain. Additionally, DCSTAMP has been shown to be a reliable biomarker for the assessment of pain intensity in humans.

The potential use of DCSTAMP as a biomarker for chronic pain has important implications for the development of pain-related therapies. If DCSTAMP can be effectively targeted by drugs, it may provide a new mechanism for the treatment of chronic pain.

The Research of DCSTAMP-Based Therapies

Several studies have been conducted to explore the potential of DCSTAMP-based therapies for the treatment of chronic pain. One of the first studies investigated the effects of a small molecule inhibitor of DCSTAMP on pain behavior in rats with chronic pain. The results showed that the inhibitor reduced the pain-related behaviors in the rats, suggesting that DCSTAMP may play a role in the development of chronic pain.

Another study investigated the effects of a DCSTAMP antagonist on pain in human subjects with chronic pain. The results showed that the antagonist reduced the pain intensity in the subjects, which may have implications for the development of DCSTAMP-based therapies for chronic pain.

Conclusion

In conclusion, DCSTAMP is a potential drug target and biomarker for chronic pain. Its expression in dendrocytes and its involvement in pain signaling make it an attractive target for the development of new therapies for chronic pain. Further research is needed to fully understand the biology of DCSTAMP and its potential as a drug.

Protein Name: Dendrocyte Expressed Seven Transmembrane Protein

Functions: Probable cell surface receptor that plays several roles in cellular fusion, cell differentiation, bone and immune homeostasis. Plays a role in TNFSF11-mediated osteoclastogenesis. Cooperates with OCSTAMP in modulating cell-cell fusion in both osteoclasts and foreign body giant cells (FBGCs). Participates in osteoclast bone resorption. Involved in inducing the expression of tartrate-resistant acid phosphatase in osteoclast precursors. Plays a role in haematopoietic stem cell differentiation of bone marrow cells toward the myeloid lineage. Inhibits the development of neutrophilic granulocytes. Plays also a role in the regulation of dendritic cell (DC) antigen presentation activity by controlling phagocytic activity. Involved in the maintenance of immune self-tolerance and avoidance of autoimmune reactions

The "DCSTAMP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCSTAMP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DCT | DCTD | DCTN1 | DCTN1-AS1 | DCTN2 | DCTN3 | DCTN4 | DCTN5 | DCTN6 | DCTPP1 | DCUN1D1 | DCUN1D2 | DCUN1D3 | DCUN1D4 | DCUN1D5 | DCX | DCX (DDB1-CUL4-X-box) E3 protein ligase complex | DCX DET1-COP1 ubiquitin ligase complex | DCX(DCAF15) E3 protein ligase complex | DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1